Dermata Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
DRMA$0.71-7.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets: | ||
| Cash and cash equivalents | $3,161,570 | $7,438,135 |
| Prepaid expenses and other current assets | 372,318 | 540,499 |
| Total assets | $3,533,888 | $7,978,634 |
| Liabilities and Stockholders’ Equity: | ||
| Liabilities: | ||
| Accounts payable | $808,011 | $866,028 |
| Accrued and other current liabilities | 1,164,783 | 757,588 |
| Total liabilities | 1,972,794 | 1,623,616 |
| Commitments and Contingencies (see Note 7) | ||
| Stockholders’ Equity: | ||
| Common Stock, par value $0.0001, 250,000,000 shares authorized as of December 31, 2024, and 2023; 2,517,768 and 261,998 shares issued and outstanding as of December 31, 2024, and 2023, respectively. | 252 | 26 |
| Additional paid-in capital | 67,236,181 | 59,742,870 |
| Accumulated deficit | (65,675,339) | (53,387,878) |
| Total stockholders’ equity | 1,561,094 | 6,355,018 |
| Total liabilities and stockholders’ equity | $3,533,888 | $7,978,634 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.